Folate and Canker Sores — Deficiency, MTHFR, and What to Take

TL;DR

Folate deficiency is identified in a meaningful subset of recurrent aphthous stomatitis (RAS) patients across multiple studies — estimates range from 14–38% of RAS patients having below-normal serum folate versus 3–10% of controls. Correcting folate deficiency reduces outbreak frequency. The complication: roughly 40% of the population carries a common MTHFR gene variant that significantly impairs conversion of dietary folic acid into 5-methyltetrahydrofolate (5-MTHF), the bioactive form the body actually uses. If you're in this group and supplementing with standard folic acid, you may see minimal benefit. The practical recommendation: supplement with methylfolate (the pre-converted form, also called 5-MTHF or L-methylfolate) rather than folic acid, particularly if you've tried folic acid before without effect.

Folate's Role in Oral Mucosal Health

Folate (Vitamin B9) is a B-vitamin essential for DNA synthesis, cell division, and methylation reactions. It is particularly critical in rapidly dividing tissues — and the oral mucosa is one of the most rapidly renewing epithelial surfaces in the body. Oral mucosal cells turn over every 7–14 days.

When folate is deficient:

• DNA synthesis is impaired in rapidly dividing epithelial cells — this produces abnormal cell maturation and increases vulnerability to ulceration
• Homocysteine accumulates — folate is required to remethylate homocysteine to methionine; elevated homocysteine is directly cytotoxic to endothelial and epithelial cells
• Immune cell production is reduced — lymphocyte proliferation and natural killer cell activity both depend on adequate folate
• Mucosal integrity weakens — the barrier function of the oral epithelium depends on normal cell turnover

The result is mucosa that is thinner, more vulnerable to minor trauma, and slower to repair — all conditions that increase the probability and severity of aphthous ulcers.

The Evidence: Folate in RAS Patients

Multiple studies across different populations have identified folate deficiency at elevated rates in RAS patients compared to controls:

Wray et al. (1975 — PMID: 1165839) — One of the earliest systematic evaluations: found B12, folate, or iron deficiency in 20% of 330 RAS patients. Among patients with deficiency, correction of the deficient nutrient led to significant clinical improvement in outbreak frequency.

Challacombe et al. (1983 — PMID: 6301481) — Serum folate levels in RAS patients were significantly lower than controls in a British cohort. Patients with major aphthous ulcers had lower levels than those with minor aphthous ulcers.

Field et al. (1987 — PMID: 3473407) — Confirmed lower serum folate in RAS patients and found that 18% of their RAS cohort was below the lower limit of normal for serum folate.

Nolan et al. (1991 — PMID: 2017188) — Prospective study finding hematinic deficiencies (B12, folate, iron) in 20% of RAS patients. Supplementation in deficient patients reduced clinical severity.

The evidence base is consistent but important to characterize honestly: most of these are deficiency-correction studies — they demonstrate that correcting folate deficiency helps patients who are deficient. There is no RCT demonstrating that supplementing folate in non-deficient RAS patients prevents outbreaks the way Vitamin B12 supplementation was shown to work even in non-deficient patients (Volkov et al., 2009 — PMID: 19530214).

If you're not folate deficient, the case for folate supplementation is weaker. If you are deficient — or haven't tested — correction is a reasonable first step.

The MTHFR Problem: Why Folic Acid May Not Work for You

This is the piece that most online advice misses.

Folic acid — the synthetic form of folate in most supplements and fortified foods — is not bioactive. It must be converted through a four-step enzymatic pathway before the body can use it. The final and rate-limiting step is catalyzed by an enzyme called MTHFR (methylenetetrahydrofolate reductase), which converts 5,10-methyleneTHF into 5-methylTHF (5-MTHF), the active circulating form.

The MTHFR gene is polymorphic. Two variants are clinically relevant:

• C677T — Reduces MTHFR enzyme activity by approximately 30–65% in heterozygotes and up to 70% in homozygotes
• A1298C — Moderate activity reduction; compound heterozygosity (one copy of each) produces clinically significant impairment

Population prevalence: The C677T variant is carried by approximately 40–60% of most populations in heterozygous form (one copy); 10–15% are homozygous (two copies). Prevalence varies by ancestry — higher in southern European, Mexican, and some Middle Eastern populations.

The practical consequence: In people with significant MTHFR impairment, supplementing folic acid may not meaningfully raise 5-MTHF levels. Unmetabolized folic acid can accumulate and may actually competitively inhibit folate receptors, potentially worsening the functional deficiency.

The solution: Supplement with 5-methyltetrahydrofolate (5-MTHF) directly, also sold as:

• L-methylfolate
• Methylfolate
• Levomefolic acid (the pharmaceutical form)
• (5-MTHF) on product labels

This form bypasses the MTHFR conversion step entirely. It is absorbed and available regardless of your MTHFR genotype.

Special Populations with Higher Folate Depletion Risk

Beyond MTHFR, several clinical scenarios elevate folate depletion risk and increase the canker sore connection:

Crohn's Disease and IBD

Crohn's disease reduces folate absorption through multiple mechanisms: small intestinal inflammation reduces absorptive surface area, sulfasalazine (a common Crohn's medication) competitively inhibits folate absorption, and methotrexate — used in moderate-to-severe IBD — directly antagonizes folate. Crohn's patients have both a high rate of RAS (oral aphthous ulcers are an extraintestinal manifestation of IBD in 5–10% of Crohn's patients) and a high rate of folate depletion. See Canker Sores and Crohn's Disease.

Celiac Disease

Celiac disease damages the proximal small intestine — where folate absorption primarily occurs — through villous atrophy. Folate malabsorption is a recognized consequence of untreated celiac, and RAS is an extraintestinal presentation of celiac in a subset of patients.

Pregnancy

Folate requirements roughly double during pregnancy due to fetal development demands. Pregnant patients on marginal folate intake may develop functional deficiency. See Canker Sores and Pregnancy.

Alcohol Use

Alcohol directly interferes with folate metabolism and renal excretion. Chronic alcohol use is one of the most common causes of folate deficiency in clinical practice.

Metformin Use

Metformin, widely used for type 2 diabetes, reduces folate and B12 absorption via mechanisms affecting intestinal transporters. Long-term metformin users should monitor both.

Testing Before Supplementing

Rather than supplementing blind, consider getting your folate status tested. A standard metabolic panel with B vitamins typically includes:

• Serum folate — reflects recent dietary intake (last 1–2 weeks); can be normal despite tissue deficiency if you recently ate well
• RBC folate — a better long-term marker; reflects tissue stores over the prior 3 months
• Homocysteine — elevated homocysteine is a functional indicator of folate (or B12) deficiency even when serum levels appear normal

If you're already investigating canker sore causes with your doctor, asking for this panel costs little and gives you useful data. A result at the lower end of normal — even technically "in range" — may still be clinically relevant for oral mucosal health.

What to Take

Preferred form: 5-MTHF (methylfolate), not folic acid — for the MTHFR reasons above.

Dose: 400–800mcg/day of methylfolate for deficiency correction and prevention. This aligns with standard supplemental doses. Higher doses (up to 1mg/day) are used in some clinical protocols for documented deficiency.

Combination products: Folate and Vitamin B12 are metabolically linked — both are required for homocysteine remethylation, and deficiency in either elevates homocysteine. A combination methylfolate + methylcobalamin (active B12) supplement addresses both simultaneously. This is particularly rational given that both nutrients are consistently deficient in RAS patients and that the mechanisms overlap.

This product provides 1,000mcg methylcobalamin + 400mcg methylfolate — both in bioactive forms that bypass conversion enzyme requirements. One lozenge covers the methylfolate dose alongside the B12 dose shown effective in RCTs.

Dietary Sources

If supplementation feels excessive and your deficiency is marginal, these are the highest-folate foods:

The caveat: cooking destroys 50–90% of food folate. Raw preparation maximizes retention. And again — if you have a meaningful MTHFR variant, food folate still needs to go through the same enzymatic conversion pathway. Dietary increases help but may not fully correct functional deficiency in high-MTHFR-impact individuals.

Folate vs. Vitamin B12: Which Matters More?

For canker sores specifically, Vitamin B12 has stronger evidence — there is an RCT (Volkov et al., 2009) showing benefit even in non-deficient patients, which is the gold standard. Folate's evidence is concentrated in deficiency-correction studies.

However, because both nutrients work together in the same methylation pathway, and because deficiency in one can mask deficiency in the other (folate supplementation can correct the hematological signs of B12 deficiency while neurological damage progresses — a reason not to supplement high-dose folic acid alone), testing both and supplementing both in their active forms is the rational approach.

The two are not competing — they're complementary. The combination product above provides both.